{"id":823266,"date":"2025-03-07T17:18:03","date_gmt":"2025-03-07T22:18:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/"},"modified":"2025-03-07T17:18:03","modified_gmt":"2025-03-07T22:18:03","slug":"vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/","title":{"rendered":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCHESTER, N.Y., March  07, 2025  (GLOBE NEWSWIRE) &#8212; Vaccinex, Inc. (OTC: VCNX) (\u201cVaccinex\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (\u201cNasdaq\u201d) of its decision to delist the Company\u2019s shares of common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.<\/p>\n<p align=\"justify\">Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.<\/p>\n<p align=\"justify\">The Company\u2019s decision to delist follows its receipt of notice dated December 16, 2024, that the Nasdaq Hearings Panel had determined to delist the Company\u2019s securities from Nasdaq, and the subsequent suspension of trading. Nasdaq would have otherwise filed a Form 25 in due course.<\/p>\n<p align=\"justify\">The Company plans to continue to focus on development of its lead product, pepinemab, to treat Alzheimer\u2019s disease and cancer through partnerships, grants and other financing avenues.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Vaccinex Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company\u2019s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents infiltration and activation of immune cells in tumors. Pepinemab was studied as a monotherapy in the Phase 1b\/2 SIGNAL-AD study in Alzheimer\u2019s Disease, and the Company has previously published promising Phase 2 data in Huntington\u2019s disease. Vaccinex believes pepinemab could also be an important contributor to combination therapy in AD. In oncology, pepinemab is being evaluated in combination with KEYTRUDA\u00ae\u00a0in the Phase 1b\/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO\u00ae in a Phase 1b\/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma.<\/p>\n<p align=\"justify\">Vaccinex\u00a0has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with\u00a0Merck Sharp &amp; Dohme Corp, a subsidiary of Merck and Co, Inc.\u00a0 Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">KEYTRUDA is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co. Inc.,\u00a0Kenilworth, NJ, USA. BAVENCIO\u00ae\/avelumab is provided by Merck KGaA, Darmstadt,\u00a0Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer.<\/p>\n<p align=\"justify\">\n        <strong>About Pepinemab<\/strong>\n      <\/p>\n<p align=\"justify\">Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton in cells and lead to loss of homeostatic functions of astrocytes and other glial cells in the brain and of dendritic cells in immune tissue. Pepinemab appears to have been well-tolerated with a favorable safety profile in multiple clinical trials in different neurological and cancer indications.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">To the extent that statements contained in this press release are not descriptions of historical facts regarding\u00a0Vaccinex, Inc. (\u201cVaccinex,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d), they may be forward-looking statements reflecting management\u2019s current beliefs and expectations. Such statements include, but are not limited to, statements identified by words such as \u201cmay,\u201d \u201cwill,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cexpects,\u201d and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). These statements include, among others, those regarding the expected timing of the delisting from Nasdaq and expected benefits of delisting. These statements are based on our current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled \u201cRisk Factors\u201d in our periodic reports filed with the\u00a0Securities and Exchange Commission and the other risks and uncertainties described in Vaccinex\u2019s most recent year-end Annual Report on Form 10-K and subsequent SEC filings.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Elizabeth Evans, PhD<br \/>Chief Operating Officer, Vaccinex, Inc.<br \/>(585) 766-2033<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vOIF6yf-rZhOk8cthqwRUbAawZakqAgFlhw-nhVuK_WMK_VelBXolb8JKuP5CAcc7HzZLbteE6NzC3P2a5LvbX5YFeY3WuT0k6SBKfcDH8M=\" rel=\"nofollow\" target=\"_blank\">eevans@vaccinex.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjcyYmRiZWYtZjYxMy00OGE3LTkyNzMtNGI5Mzc4MzNhMDdmLTEwMjgxNzYtMjAyNS0wMy0wNy1lbg==\/tiny\/Vaccinex-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) &#8212; Vaccinex, Inc. (OTC: VCNX) (\u201cVaccinex\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (\u201cNasdaq\u201d) of its decision to delist the Company\u2019s shares of common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq. The Company\u2019s decision to delist follows its receipt &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823266","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) &#8212; Vaccinex, Inc. (OTC: VCNX) (\u201cVaccinex\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (\u201cNasdaq\u201d) of its decision to delist the Company\u2019s shares of common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq. The Company\u2019s decision to delist follows its receipt &hellip; Continue reading &quot;Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-07T22:18:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market\",\"datePublished\":\"2025-03-07T22:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/\"},\"wordCount\":733,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/\",\"name\":\"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\",\"datePublished\":\"2025-03-07T22:18:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/","og_locale":"en_US","og_type":"article","og_title":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk","og_description":"ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) &#8212; Vaccinex, Inc. (OTC: VCNX) (\u201cVaccinex\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (\u201cNasdaq\u201d) of its decision to delist the Company\u2019s shares of common stock, par value $0.0001 per share (the \u201cCommon Stock\u201d), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq. The Company\u2019s decision to delist follows its receipt &hellip; Continue reading \"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-07T22:18:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market","datePublished":"2025-03-07T22:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/"},"wordCount":733,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/","name":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=","datePublished":"2025-03-07T22:18:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MTIwNiM2Nzk2ODY2IzIwMTY2MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823266"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}